Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...
Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here ...
A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...
Moderna swung to a loss in the last three months of the year after an early launch of its updated Covid-19 vaccine shifted sales out of the fourth quarter.
Biotechnology company Moderna (NASDAQ:MRNA) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 65.6% year ...
The company is now expecting 2025 revenue to range from $1.5 billion to $2.5 billion, with a midpoint of $2.0 billion, while FactSet is expecting $2.4 billion. Most of that will come in the second ...
In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal anticipated cuts to the company’s digital team.
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...
7hon MSN
Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...
Moderna Inc.'s stock fell 2.9% early Friday, after the biotech posted a wider-than-expected fourth-quarter loss and offered soft guidance for 2025, offsetting a revenue beat.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results